Sinco Pharmaceuticals Holdings (HKG:6833) Takes On Some Risk With Its Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. As with many other companies Sinco Pharmaceuticals Holdings Limited (HKG:6833) makes use of debt. But is this debt a concern to shareholders?

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Why Does Debt Bring Risk?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.

What Is Sinco Pharmaceuticals Holdings's Net Debt?

As you can see below, Sinco Pharmaceuticals Holdings had CN¥221.6m of debt at June 2025, down from CN¥327.3m a year prior. However, it does have CN¥232.6m in cash offsetting this, leading to net cash of CN¥11.0m.

How Healthy Is Sinco Pharmaceuticals Holdings' Balance Sheet?

We can see from the most recent balance sheet that Sinco Pharmaceuticals Holdings had liabilities of CN¥1.19b falling due within a year, and liabilities of CN¥2.80m due beyond that. Offsetting this, it had CN¥232.6m in cash and CN¥787.0m in receivables that were due within 12 months. So its liabilities total CN¥176.6m more than the combination of its cash and short-term receivables.

This deficit isn't so bad because Sinco Pharmaceuticals Holdings is worth CN¥379.9m, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. But we definitely want to keep our eyes open to indications that its debt is bringing too much risk. Despite its noteworthy liabilities, Sinco Pharmaceuticals Holdings boasts net cash, so it's fair to say it does not have a heavy debt load!

View our latest analysis for Sinco Pharmaceuticals Holdings

It is just as well that Sinco Pharmaceuticals Holdings's load is not too heavy, because its EBIT was down 28% over the last year. Falling earnings (if the trend continues) could eventually make even modest debt quite risky. There's no doubt that we learn most about debt from the balance sheet. But it is Sinco Pharmaceuticals Holdings's earnings that will influence how the balance sheet holds up in the future. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. Sinco Pharmaceuticals Holdings may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the last three years, Sinco Pharmaceuticals Holdings recorded negative free cash flow, in total. Debt is far more risky for companies with unreliable free cash flow, so shareholders should be hoping that the past expenditure will produce free cash flow in the future.

Summing Up

Although Sinco Pharmaceuticals Holdings's balance sheet isn't particularly strong, due to the total liabilities, it is clearly positive to see that it has net cash of CN¥11.0m. Despite the cash, we do find Sinco Pharmaceuticals Holdings's EBIT growth rate concerning, so we're not particularly comfortable with the stock. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. Be aware that Sinco Pharmaceuticals Holdings is showing 2 warning signs in our investment analysis , and 1 of those is significant...

If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.